Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label PSI-938. Show all posts
Showing posts with label PSI-938. Show all posts
Wednesday, August 24, 2011

PSI-938 Receives Fast Track from the FDA for Hepatitis C

›
Pharmasset, Inc. PRINCETON, N.J., Aug. 24, 2011 -- /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation fro...
Wednesday, March 23, 2011

Hepatitis; PSI-938 and PSI-7977 Breaking Down The Media Frenzy

›
Last week we had a sneak peek at a small study being presented at this months EASL. According to the recent media frenzy Pharmassets two ora...
2 comments:
Thursday, January 6, 2011

Hepatitis C Drugs PSI-7977/PSI-938 interim analyses announced Jan 2011

›
Pharmasset Reports Positive Results from its HCV Clinical Programs - PSI-7977 400mg QD with pegylated interferon and ribavirin was generally...
Tuesday, November 30, 2010

Hepatitis C: PSI-7977 and PSI-938 Pharmasset Initiates Dosing

›
Pharmasset Initiates Dosing in a Combination Study of PSI-7977 and PSI-938 for Chronic Hepatitis C - Phase 1 combination study of a pyr...
Sunday, November 7, 2010

Hepatitis C Drugs: R7128 with the protease inhibitor R7227

›
Wednesday, November 3, 2010 Pharmasset Riding High on Nucs Pharmasset is a biotech company focused on the development of HCV therapeutics. I...
Thursday, October 28, 2010

Pharmasset Positive Preliminary Data with PSI-938 /Treatment of Hepatitis C

›
Pharmasset Reports Positive Preliminary Antiviral Data with PSI-938 for the Treatment of Hepatitis C . -- PSI-938 achieves a median 3.94 to ...